Increasing Trends in Male Reproductive Disorders, Environmental Exposures, Implications for Human Health

Half of all young men’s semen quality does not meet the reference standard of the World Health Organization

On this call, Dr. Skakkebaek presented his concerns about increasing trends in male reproductive disorders, including the significant global increase in incidence of germ cell tumors. He and colleagues from all over the world demonstrated that over half of all young men’s semen quality does not meet the reference standard of the World Health Organization.

Dr. Skakkebaek presented evidence linking testicular cancer, poor semen quality, childlessness, and rapidly decreasing fertility rates. He showed how there is little doubt that environmental factors, most likely associated with modern lifestyles, have – in a broad sense – had an adverse influence on male reproductive health. He and his group are examining a fundamental role that exposure to endocrine-disrupting chemicals may play in these trends, trends that in a few decades will result in decreasing populations in industrialized countries, and believes collaborative research is required to identify the causes of these adverse trends.

Sources and more information

Out of the Past

Old Exposures, Heritable Effects, and Emerging Concepts for Autism Research

The presentation highlights a significant gap in autism research: what factors might be driving the heterogenous de novo genomic errors seen in autism?

Sources:
More DES DiEthylStilbestrol Resources

Diethylstilbestrol Studies with Ethical Violations

Research ethics: where do you draw the line?

1950’s illegal studies that violated the Hippocratic Oath, the Nuremberg Code, and the Declaration of Helsinki.

Sources:
More DES DiEthylStilbestrol Resources

World Cancer Day 2016 Key Messages

What can YOU do – as an individual – to help prevent and fight cancer?

Just as cancer affects everyone in different ways, all people have the power to take various actions to reduce the impact that cancer has on individuals, families and communities.

World Cancer Day is a chance to reflect on what you can do, make a pledge and take action. Whatever you choose to do ‘We can. I can.’ make a difference to the fight against cancer.

More information

Endocrine Disrupting Chemicals in Healthcare

HCWH Europe held a webinar on EDCs in the healthcare sector in Sept. 2014

HCWH Europe held a webinar on endocrine disruptors in the healthcare sector in September 2014. The discussion was moderated by Laurel Berzanskis, Chemicals and Pharmaceuticals Policy Officer for HCWH Europe. Speakers included Dr Gavin ten Tusscher (Westfriesgasthuis, the Netherlands) and Dr R. Thomas Zoeller (University of Massachusetts Amherst, USA).

Sources and more information

Tackling Antimicrobial Resistance

How healthcare professionals, and those working in local authorities, can bring down levels of antibiotic prescribing

The pressure on healthcare professionals to prescribe antibiotics is great. But we need to conserve antibiotics and use them appropriately or we risk losing the power of these medicines.

  1. The scale of the problem
  2. Why we need to act now
  3. Antibiotic prescribing in England
  4. How we can put down on inappropriate prescribing
  5. We all have a role to play

Sources and more information

Methodology for EU EDC screening

Impact assessment on criteria to identify endocrine disruptors – technical meeting on the Joint Research Center methodology

European Commission Joint Research Center presents chemical screening methodology for the impact assessment on criteria to identify endocrine disruptors

A technical meeting on the JRC methodology for evidence screening of chemicals developed in the context of the Impact Assessment on criteria to identify Endocrine Disruptors took place on 6 November 2015 in Brussels.

The aim of this technical meeting was to present to Member States, Members of the European Parliament, countries from outside the EU and stakeholders the methodology developed by the JRC to estimate which chemicals may fall under the different options for criteria to identify endocrine disruptors as outlined in the roadmap. This methodology was developed in the framework of the impact assessment carried out by the European Commission on criteria to identify endocrine disruptors, in the context of the Plant Protection Products Regulation (EC) 1107/2009 and the Biocidal Products Regulation (EU) 528/2012.

Sources and more information
  • EU Public Health press release.
  • Selection of chemical substances to be screened in the context of the impact assessment on criteria to identify endocrine disruptors, EU PDF.
  • Watch it Full Screen on via SlideShare.
  • DES Daughter Network on SlideShare.

Mammography Screening SlideShare Presentation

Why was screening implemented? What is overdiagnosis?

  • Why was screening implemented?
  • What is overdiagnosis?
  • The evidence for overdiagnosis
  • Available data
  • Facts from recent studies
  • Risks of screening
  • The illusion of early detection
  • Harms due to overdiagnosis
  • Benefit-risk balance
  • So, what to do?
Sources:

Gender Dysphoria, Transsexualism, and Disorders of Sexual Differentiation in DES Sons

DES Sons International Network slideshow presentation, 2004

by Scott P. Kerlin, Ph.D.

DES Sons International Network

The Presence of Gender Dysphoria, Transsexualism, and Disorders of Sexual Differentiation in Males Prenatally Exposed to Diethylstilbestrol: Initial Evidence from a 5-Year Study.

Sources:

More DES DiEthylStilbestrol Resources

Dépister le Cancer du Sein?

Présentation Diaporama Bénéfice Potentiel et Risques

Le dépistage organisé du cancer du sein, généralisé en France depuis 2004 et proposé aux femmes de 50 à 74 ans, fait l’objet de controverses. Celles-ci, publiées dans des revues scientifiques de premier plan, ont été longtemps minimisées auprès du grand public.

Les doutes portent sur un faible bénéfice et des risques avérés. Ces derniers sont essentiellement les fausses alertes, c’est à dire l’annonce d’une lésion mammographique qui ne s’avère pas réelle, et le surdiagnostic. Le surdiagnostic est la découverte d’un cancer qui n’aurait pas affecté la santé de la femme de son vivant, s’il n’avait pas été détecté. Le bénéfice s’avère beaucoup plus faible que présenté officiellement, en raison notamment du faible risque en valeur absolue de mourir de ce cancer, et de la faible efficacité du dépistage.

De ce constat est née une brochure indépendante, délivrant une information claire, qui se veut loyale, aussi complète que possible et facilement accessible. Elle est téléchargeable gratuitement directement sur la page d’accueil de cancer-rose.

Seize auteurs l’ont élaborée. Destinée à la lectrice concernée par le dépistage, elle est aussi pensée comme aide au praticien démuni face aux interrogations d’une patiente.

L’objectif de cette brochure, (unique en langue française alors qu’il en existe p.ex. en Allemagne pour les femmes) est de donner aux femmes le pouvoir de décider de façon rationnelle et sans être culpabilisées. Chacune se fera ainsi son opinion au travers des meilleures sources scientifiques disponibles. Même si le dépistage du cancer du sein est un programme dit de santé publique, il n’en reste pas moins que la participation est une décision individuelle qui ne peut être prise qu’en connaissance de cause, ni imposée ni subie.

Linkedin SlideShare